Insmed, Inc. (NASDAQ:INSM) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET

Company Participants

Bryan Dunn - Executive Director, Investor Relations
William Lewis - Chairman, President & CEO
Eugene Sullivan - Chief Product Strategy Officer & Chief Scientific Officer
Sara Bonstein - CFO

Conference Call Participants

Andrea Tan - Goldman Sachs & Co.
Jessica Fye - JPMorgan Securities
Leon Wang - Barclays Capital
Joseph Schwartz - Leerink Partners
Nicole Germino - Truist Securities
Jason Zemansky - Bank of America Merrill Lynch
Ritu Baral - Cowen & Co.
Jeff Hung - Morgan Stanley
Liisa Bayko - Evercore ISI
Jennifer Kim - Cantor Fitzgerald
Stephen Willey - Stifel

Operator

Thank you for standing by. My name is Dee, and I will be your conference operator today. At this time, I would like to welcome everyone to the Insmed's First Quarter 2024 Financial Results Call. [Operator Instructions].

I would now like to turn the call over to Bryan Dunn, Head of Investor Relations.

Bryan Dunn

Thank you, Dee. Good day, everyone, and welcome to today's conference call to discuss Insmed's first quarter 2024 financial results and provide a business update. I am joined today by Will Lewis, Chair and Chief Executive Officer; Gene Sullivan, Chief Product Strategy Officer; and Sara Bonstein, Chief Financial Officer, who will each provide prepared remarks before we open it up for your questions.

Before we start, please note that today's call will include forward-looking statements based on our current expectations. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. Please refer to our filings with the Securities and Exchange Commission for more information concerning the risk factors that could affect the Company.

Also note that our call today will include blinded observations from our ongoing Phase 2 study of TPIP in pulmonary arterial hypertension. These observations may not be representative of results once the study is completed and all data is collected and analyzed as a result, any future interim data readouts and the final data from this study may be materially different than the observations described today.

Finally, the information on today's call is for the benefit of the investment community. It is not intended for promotional purposes, and it is not sufficient for prescribing decisions.

I will now turn the call over to Will Lewis for prepared remarks.